Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BCX1777

Known as: BCX-1777 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Enzymes catalyzing the phosphorolytic cleavage of their substrates can reduce arsenate (AsV) to the more toxic arsenite (AsIII… Expand
Review
2008
Review
2008
Recently, the search for more effective and safer antineoplastic agents has led to synthesis and introduction into preclinical… Expand
Review
2007
Review
2007
Recently a few new purine nucleoside analogues (PNA) have been synthesized and introduced into preclinical and clinical trials… Expand
2006
2006
Background: Forodesine, a potent, rationally designed purine nucleoside phosphorylase inhibitor, has shown clinical activity in T… Expand
2006
2006
Background: Forodesine is a potent, rationally designed purine nucleoside phosphorylase (PNP) inhibitor that is orally… Expand
Highly Cited
2005
Highly Cited
2005
The discovery of purine nucleoside phosphorylase (PNP) deficiency and T lymphocytopenia suggested that inhibition of this enzyme… Expand
  • table 1
  • table 2
  • figure 2
  • table 3
  • figure 3
Highly Cited
2003
Highly Cited
2003
Purine nucleoside phosphorylase (PNP) deficiency in humans produces a relatively selective depletion of T cells. BCX-1777 is a… Expand
2003
2003
Reduction of the pentavalent arsenate (AsV) to the thiol-reactive arsenite (AsIII) toxifies this environmentally prevalent form… Expand
2002
2002
Purine nucleoside phosphorylase (PNP) deficiency in humans produces a relatively selective depletion of T-cells. Inhibitors of… Expand
Highly Cited
2001
Highly Cited
2001
Patients with purine nucleoside phosphorylase (PNP) deficiency present a selective T-cell immunodeficiency. Inhibitors of PNP are… Expand